Propanc Biopharma (PPCB) investor relations material

Executive summary

• Focused on developing PRP, a novel proenzyme therapy targeting recurrence and metastasis in solid tumors, especially pancreatic and ovarian cancers.

• No commercial revenues; operations are preclinical, with clinical trial preparations underway.

• Significant R&D progress, including collaborations with European universities and ongoing patent protection efforts.

• Company completed a public offering and private placements to fund operations.

Financial highlights

• No revenue for fiscal years ended June 30, 2026 and 2025.

• Net loss decreased to $18.9M in 2026 from $58.9M in 2025, mainly due to lower stock-based compensation and consulting expenses.

• Operating expenses for 2026 were $18.2M, down from $57.3M in 2025.

• Cash balance at June 30, 2026 was $832K, up from $12K in 2025.

• Accumulated deficit reached $144.5M as of June 30, 2026.

Outlook and guidance

• CTA submission for PRP planned for Q4 2026, with Phase Ib clinical trial initiation targeted for early 2027, pending additional financing.

• Anticipated R&D and overhead expenses to increase as clinical development progresses.

• Company will require further equity or debt financing to sustain operations and clinical milestones.